Showing 7611-7620 of 8465 results for "".
- DermTech: Carcinome Clinical Study Enrollment Completehttps://practicaldermatology.com/news/dermtech-carcinome-clinical-study-enrollment-complete/2457745/DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study. The goal of the Carcinome™ study is to develop a non-invasive genomic test to differentiate basal cell carcinoma (BCC) and squamous cell
- Skincare on Trial: Revision Introduces New Patient-Friendly Optionhttps://practicaldermatology.com/news/skincare-on-trial-revision-introduces-new-patient-friendly-option/2457752/Revision Skincare has introduced a collection of five comprehensive 45-day trial regimens they say are designed to address the needs of
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- FDA Frowns on Evolus' Botox Rivalhttps://practicaldermatology.com/news/fda-frowns-on-evolus-botox-rival/2457763/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat
- Innovations in Skin of Color Dermatology Award Goes to Eliot Battle, MDhttps://practicaldermatology.com/news/innovations-in-skin-of-color-dermatology-award-goes-to-eliot-battle-md/2457775/Eliot Battle, MD has been awarded the Innovations in Skin of Color Dermatology Award. The award was presented by The&nbs
- Sensus Appoints Rita Gable as VP of Sales, Oncologyhttps://practicaldermatology.com/news/sensus-appoints-rita-gable-as-vp-of-sales-oncology/2457783/Sensus Healthcare, Inc. has appointed Rita Gable as Vice President of Sales – Oncology. Ms. Gable, who will report to Joe Sardano, Sensus CEO, has 15 years of sales e
- DermTech Partners with Melanoma Research Foundation to Support Miles for Melanomahttps://practicaldermatology.com/news/dermtech-partners-with-melanoma-research-foundation-to-support-miles-for-melanoma/2457781/DermTech, Inc. is partnering with the Melanoma Research Foundation in support of five Miles for Melanoma Runs/Walks held throughout the US, kicking off this month during Melanoma Awareness
- Bath Emollients Don't Add Much to Standard Eczema Carehttps://practicaldermatology.com/news/bath-emollients-dont-add-much-to-standard-eczema-care/2457784/Emollient bath additives provide no meaningful benefit when used in addition to standard eczema care in children, according to research in the BMJ. UK researchers, led by Miriam Santer, MBBChir
- Cellulite Market Expected to Growhttps://practicaldermatology.com/news/cellulite-market-expected-to-grow/2457792/The cellulite treatment market is expected to grow worldwide, as the obesity epidemic grows. Findings are in the comprehensive research report by Future Market Insights entitled “Cellulite Treatment Market